<DOC>
	<DOCNO>NCT02105987</DOCNO>
	<brief_summary>This study 48-week , Phase IIIb , randomly assign , open-label , active-controlled , multicenter , parallel group , non-inferiority study . This study design demonstrate non-inferior antiviral activity switch Abacavir ( ABC ) 600 milligram ( mg ) /Dolutegravir ( DTG ) 50 mg/Lamivudine ( 3TC ) 300 mg fixed-dose combination ( FDC ) compare continue subject 's current suppressive regimen 24 week . The study conduct approximately 538 Human Immunodeficiency Virus -1 ( HIV-1 ) infect individual stable suppressive combination antiretroviral therapy ( cART ) 2 Nucleoside reverse transcriptase inhibitor ( NRTIs ) plus either protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , integrase inhibitor ( INI ) . Eligible subject randomly assign 1:1 continue current regimen ( approximately 269 subject ) switch ABC/DTG/3TC FDC ( approximately 269 subject ) daily 24 week . At Week 24 , individual originally randomly assign continue current regimen switch ABC/DTG/3TC FDC follow additional 24 week . Individuals initially randomly assign ABC/DTG/3TC FDC continue treatment arm additional 24 week . A pharmacokinetic ( PK ) substudy conduct small number site ( approximately 10 ) evaluate predose DTG concentration well residual drug concentration efavirenz ( EFV ) , nevaripine ( NVP ) , amprenavir ( APV ) tipranavir ( TPV ) subgroup subject switch EFV , NVP , fosamprenavir/ritonavir ( FPV/r ) tipranavir/ritonavir ( TPV/r ) .</brief_summary>
	<brief_title>A Phase IIIb Study Safety , Efficacy , Tolerability Switching Fixed-dose Combination Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Be able understand comply protocol requirement , instruction , restriction ; Be likely complete study plan ; Be consider appropriate candidate participation investigative clinical trial oral medication ( e.g. , active substance abuse , acute major organ disease , plan longterm work assignment country , etc. ) . Signed date write informed consent obtain subject subject 's legal representative prior screen HIV1 infect men woman &gt; =18 year age ; A female may eligible enter participate study : . Is nonchildbearing potential either defined postmenopausal ( 12 month spontaneous amenorrhea &gt; =45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy , bilateral oophorectomy , A female may eligible enter participate study : b . Is childbearing potential negative pregnancy test Screening Day 1 agrees use one follow method contraception avoid pregnancy : Complete abstinence intercourse 2 week prior administration study drug , throughout study , least 2 week discontinuation study drug ; Double barrier method ( e.g. , male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ; Male partner sterilization prior female subject 's entry study male sole partner subject ; Approved hormonal contraception subject randomly assign ABC/DTG/3TC arm approve hormonal contraception plus barrier method subject assign continued antiretroviral therapy arm ; Any method publish data show expected failure rate &lt; 1 % per year . Any contraception method must use consistently , accordance approve product label least 2 week discontinuation study drug . A childbearing potential female subject start study use complete abstinence contraceptive method decide become sexually active must use double barrier method either bridge approve hormonal contraception ( possible ) method choice maintain moment onwards . All subject participate study counsel safe sexual practice include use effective barrier method ( e.g. , male condom/spermicide ) . Within last year , 2 consecutive plasma HIV1 Ribonucleic acid ( RNA ) measurement &lt; 50 copies/millilitres ( c/mL ) plasma HIV1 RNA &lt; 50 c/mL Screening ( &lt; 75 b Deoxyribonucleic acid [ bDNA ] consider equal &lt; 50 c/mL ) ; Subjects present initial screen viral load 50 200 c/mL retested within screen period . Must current regimen ( whether first second line Combination antiretroviral therapy [ cART ] ) least 6 month prior Screening ; Acceptable stable cART regimens prior Screening include : • Boosted PI ( Atazanavir [ ATV ] ) unboosted ) + 2 NRTIs , NNRTI + 2 NRTIs , • INI + 2 NRTIs . For subject INI , INI Screening must RAL Elvitegravir ( EVG ) Any switch second line regimen , define change single drug multiple drug simultaneously , must occur due tolerability and/or safety concern . Subject must achieve plasma HIV1 RNA level &lt; 50 c/mL within 6 month start initial cART regimen plasma HIV1 RNA level &gt; 200 c/mL follow initial suppression ; Documentation subject negative human leukocyte antigen ( HLA ) B*5701 allele ; Exclusionary Medical Conditions Women breastfeed ; Any evidence active ( Centers Disease Control Prevention [ CDC ] Category C ) disease . Exceptions include cutaneous Kaposi 's sarcoma require systemic therapy historic CD4+ cell count &lt; 200 cells/cubic millimeter ( mm ) . Subjects degree hepatic impairment ; Subjects positive hepatitis B virus surface antigen ( +HBsAg ) Screening anticipate need hepatitis C virus ( HCV ) therapy study ; History presence allergy study drug component drug class ; Ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous cell carcinoma , cervical intraepithelial neoplasia ; localize malignancy require agreement investigator study medical monitor inclusion subject ; Subjects , investigator 's judgment , pose significant suicidality risk . Recent history suicidal behavior and/or suicidal ideation may consider evidence serious suicide risk ; Exclusionary Treatments Prior Screening Day 1 Treatment HIV1 immunotherapeutic vaccine within 90 day Screening ; Treatment follow agent within 28 day Screening : radiation therapy , cytotoxic chemotherapeutic agent , immunomodulators alter immune response ; Exposure experimental drug experimental vaccine within either 28 day , 5 halflives test agent , twice duration biological effect test agent , whichever longer , prior first dose study drug ; A history use mono dual NRTI therapy prior start cART ; Use etravirine time switch ; Use DTG time switch ; Subjects receive prohibit medication list protocol unwilling unable switch alternate medication Exclusionary Laboratory Values Clinical Assessments Screening Evidence primary viral resistance base presence resistanceassociated major PI NRTI , NNRTI , INI mutation prior resistance genotype assay result ; Any verify Grade 4 laboratory abnormality , exception Grade 4 triglyceride abnormality . A single repeat test allow screening period verify result ; Any acute laboratory abnormality Screening , , opinion investigator , would preclude subject 's participation study investigational compound ; Alanine aminotransferase ( ALT ) &gt; =5 time upper limit normal ( ULN ) , ALT &gt; =3 × ULN bilirubin &gt; =1.5 × ULN ( &gt; 35 % direct bilirubin ) ; Subject CrCl &lt; 50 mL/min use Modification Diet Renal Disease ( MDRD ) ; QTc ( Bazett ) &gt; =450 msec QTc ( Bazett ) &gt; =480 msec subject bundle branch block . The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) . The QTc base single QTc value electrocardiogram ( ECG ) obtain . Eligibility subject study participation decide investigator take consideration various country specific guideline , notwithstanding mention minimum inclusion exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Abacavir/dolutegravir/lamivudine</keyword>
	<keyword>Fixed-dose combination</keyword>
	<keyword>Once daily</keyword>
	<keyword>Trii</keyword>
	<keyword>Single-tablet regimen</keyword>
</DOC>